Checkpoint Inhibitors (CPI), namely anti-CTLA4 and anti-PD1/PD-L1 antibodies, demonstrated efficacy across multiple types of cancer. However, only subgroups of patients respond to these therapies.
Introduction
Checkpoint Inhibitors (CPI) are a new class of anti-cancer agents. These antibodies (Ab) target normal immune cells in order to stimulate the anti-tumor response. They work by blocking interactions between inhibitory receptors expressed on T cells and their ligands. In oncology, the two main classes of CPI which are the most advanced in clinical development are the anti-CTLA-4 and anti-PD-1/PD-L1 Abs. Three of these Abs have been approved by the FDA for clinical use (Table 1) . CPI can have efficacy across several types of cancer. However, only subgroups of patients respond to these drugs.
Additionally, CPI can induce "autoimmune-like" toxicities. These findings raise several questions.
What is the impact of CPI on the immune system? Are there biological markers related to their efficacy or toxicity? After a brief review of the mechanisms of action of CPI, we will present the biomarkers that have been associated with pharmacodynamics changes, therapeutic efficacy and toxicity of these treatments in clinic.
CTLA-4 pathway T-cell activation following the stimulation of its receptor (T cell receptor [TCR]) requires a second
signal which results from the interaction between the activating receptor CD28 located on the T cell surface and the CD80 (B7.1) and CD86 (B7.2) molecules expressed by the antigen-presenting cells (APC). Secondly, the activated T cell expresses CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) on its surface, an inhibitory receptor which also recognizes the CD80 and CD86 molecules, but with a much stronger affinity than CD28. The binding of CD80/CD86 to CTLA-4 then inhibits T cells. Anti-CTLA-4 Abs block this interaction and prevent T cell inhibition 
Biomarkers associated with pharmacodynamics and clinical responses to CPI
The main biological markers associated with pharmacodynamics and/or clinical responses to CPI are listed in Table 2 . A multitude of biomarkers has been studied, predominantly involving indices from the patient's tumor (tumor cells or cells from the microenvironment) or blood (circulating cells or serum). The following section provides a brief summary of each biomarker most advanced in study.
Circulating lymphocytes, neutrophils, eosinophils, and monocytes Several studies have shown that treatment with anti-CTLA-4 Ab increased the level of circulating lymphocytes 4 . This increase seems to be associated with a better clinical efficacy [5] [6] [7] . More recently, a study conducted in a 'real world' population of melanoma patients treated with ipilimumab found a correlation between baseline absolute lymphocyte count (ALC) and overall survival (OS was greater in patients with increased ALC at baseline) 8 .
Two studies evaluating an anti-PD-L1 Ab (MPDL3280A) in different cancers showed transient increase of CD8+ HLA-DR+ Ki-67+ cells early during treatment, but there was no correlation with clinical activity 9, 10 .
A study showed that the ratio between neutrophils and lymphocytes (N/L) during treatment with
Ipilimumab correlated with clinical efficacy. A N/L ratio below normal limits after 7 and 10 weeks of treatment was significantly associated with a better survival 11 .
A low level of eosinophils at baseline before treatment was associated with a better overall survival in patients treated with anti-CTLA-4 Ab (Ipilimumab) for a metastatic melanoma 12 .
Finally, a high level of CD16-expressing monocytes at baseline was found to be associated with higher response rate and lower Tregs counts in the tumor microenvironment of responding patients 13 .
CD4+ ICOS hi T cells
ICOS is a co-stimulatory receptor expressed on the surface of T cells after activation. In murine models, it has been shown that expression of ICOS is necessary for the efficacy of anti-CTLA-4 Ab.
Indeed, mice lacking ICOS or its ligand have a lower response to anti-CTLA-4 Ab than wild-type mice 14 .
In patients, it has been described that anti-CTLA-4 Ab increased the number of CD4+ ICOS hi T cells (producing IFNγ) in the blood 15, 16 and in the tumor [16] [17] [18] . .
Lactate dehydrogenase (LDH)
In some solid tumors and hematologic malignancies, a high level of LDH at baseline is frequently associated with poor prognosis. In advanced melanoma, the site(s) of metastasis and a high level of LDH at baseline are the two most significant prognostic factors 37 . Increased LDH at baseline seems to be associated with resistance to anti-CTLA-4 Ab therapy in advanced melanoma 6, 8, 38 .
Tumor-infiltrating lymphocytes (TIL)
The presence of lymphocytes within the tumor is a favorable prognostic factor in numerous cancers 39 . The lymphocyte infiltrate also seems to be a predictive factor of response to CPI. In patients with metastatic melanoma treated with anti-CTLA-4 Ab (Ipilimumab), an increase in lymphocyte infiltrate in the tumor between baseline and at three weeks after treatment initiation correlated with clinical response 40 . Moreover, in melanoma patients treated with anti-PD-1 Ab (Pembrolizumab), response rate was better in patients with high numbers of peri-and intra-tumoral CD8 T cells in their pre-treatment samples 22 . Analysis of biopsies after treatment with anti-CTLA-4 Ab (Ipilimumab) showed a correlation between a high ratio of intratumoral CD8/regulatory T cells and tumor necrosis 16, 41 . Granzyme B is a cytotoxic granule reflective of CD8 effector function. In the tumor, its expression seems to be increased after anti-PD-1 42 , anti-CTLA-4 40 . However, other studies did not confirm this correlation [51] [52] [53] [54] [55] . Table 3 .
Eosinophils
In 156 patients presenting with metastatic melanoma, the circulating eosinophils count before and during treatment with anti-CTLA-4 Ab (Ipilimumab) was associated with irAEs occurence 65 .
IL-17
In 52 patients treated with anti-CTLA-4 Ab (Ipilimumab) for metastatic melanoma, increase followed by decrease of blood IL-17 levels were respectively associated with the settling and the resolution of colitis 66 .
Gene expression profile (GEP)
Gene expression profiling performed on blood from patients treated with anti-CTLA-4 Ab (Ipilimumab) showed that, out of 10,000 probe sets tested, the increased expression of CD177 and CEACAM1 genes, two markers of neutrophil activation, was associated with digestive toxicity 67 .
Digestive infiltrate by neutrophils
A study of melanoma patients treated with anti-CTLA-4 Ab (Ipilimumab) showed that, on colon biopsies performed just before treatment initiation, lamina propria infiltration by neutrophils as well as other markers of inflammation (cryptic abscess, gland destruction, mucosal erosion) were associated with the occurrence of digestive toxicity 68 .
Lastly, several studies suggest that the occurrence of irAEs could correlate with better efficacy of anti-CTLA-4 Ab (Ipilimumab) 25, [69] [70] [71] . However, association between toxicity and efficacy is not entirely clear 72 and numerous patients respond to CPI therapy without experiencing irAEs.
Conclusions
Numerous biomarkers may reflect the pharmacodynamics of CPIs and predict their efficacy and/or their toxicity in patients. However, the relevance of these biomarkers to clinical practice and their potential for routine application remains ill-defined, and will have to be clarified in larger, prospective studies. A subset of biomarkers seem relevant and accessible enough to be part of our practices (e.g.
LDH level, absolute lymphocytes count variation); others look promising but need standardisation of current practices (e.g. measure of PD-L1 expression) and finally, some biomarkers are not yet biomarkers described so far have been tested in melanoma patients and therefore require validation in other cancer types and immunotherapeutic agents.
Patients who seem to benefit most from CPIs are those presenting with immunogenic tumors (i.e.
with a high mutational load), pre-existing immune response (intratumoral immune infiltrate) and the immune escape ligands being targeted (i.e. PD-L1 for patients treated with anti-PD-1/PD-L1 Abs).
Nevertheless, these biomarkers are not perfect. In the future, better knowledge of the mechanisms of action of CPIs in vivo should help us identify other biomarkers in order to define patients who will benefit most from these effective but costly and potentially toxic drugs.
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